Corifact, developed by CSL Behring, is a prophylactic treatment for congenital Factor XIII deficiency, a rare bleeding disorder characterized by unstable blood clots. Administered intravenously, Corifact is indicated for both adult and pediatric patients, aiding in the management of surgical bleeding and routine prophylactic treatment. While potential hypersensitivity reactions and inhibitory antibodies to Factor XIII may occur, Corifact has been proven effective in clinical trials, with common adverse reactions including joint inflammation and rash.
Derived from human blood, Corifact carries a theoretical risk of transmitting infectious agents, including viruses and the Creutzfeldt-Jakob disease agent. Thromboembolic complications have also been reported, necessitating careful monitoring in patients with known risk factors. Despite these considerations, Corifact remains a valuable treatment option, demonstrating CSL Behring's commitment to patient care and safety.
Generated from the website